

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Topical Immunomodulators (Atopic Dermatitis) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

## **Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage of **Topical Immunomodulators (Atopic Dermatitis).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at:** Pharmacy | Community Provider Portal | Kaiser Permanente

	1 - Patient Information	
Patient Name:	Kaiser Medical ID#:	Date of Birth:
2 – Provider Information		
Provider Name:	Specialty:	Provider NPI:
Provider Address:		
Provider Phone #:		
3 – Pharmacy Information		
Pharmacy Name:		
Pharmacy Phone #	Pharmacy Fax #:	
	4 – Drug Therapy Requested	
Drug 1: Name/Strength/Formulation: Sig:		
Drug 2: Name/Strength/Formulation: Sig:		
	5 – Diagnosis	
Diagnosis of Atopic Dermatitis? ☐ No ☐ Yes Severity: ☐ Mild ☐ Moderate ☐ Severe		
If "No" to above, provide details:		

## 6 - Clinical Criteria

6 – Clinical Criteria		
Criteria for Elidel, Protopic, and tacrolimus:		
1. Select indication and age for use:		
□ Elidel Mild to Moderate for ages ≥ 2 years old		
□ Protopic 0.03%: Moderate to Severe for ages ≥ 2 years old		
☐ Protopic 0.1%: Moderate to Severe for ages ≥ 16 years old		
2. And Documented of 8 weeks trial and failure (or contraindication) of one Topical corticosteroid of medium to high		
potency (i.e., mometasone, fluocinolone)?		
□ No □ Yes		
Criteria for Eucrisa and Opzelura:		
1. Select indication and age for use:		
☐ Eucrisa: Mild to Moderate for ages ≥ 3 months old		
□ Opzelura: Mild to Moderate for ages ≥ 12 years old		
- Opzerara. While to Woderate for ages - 12 years old		
Note: Opzelura is not covered for the indication of nonsegmental vitiligo in adult and pediatric patients ≥ 12 years old.		
2. Document trial and failure or contraindication:		
☐ Eucrisa- Prior trial for 30 days and failure or contraindication to:		
<ul> <li>One topical corticosteroid of medium to high potency (i.e., mometasone, fluocinolone) AND</li> </ul>		
<ul> <li>One topical calcineurin inhibitors (tacrolimus or pimecrolimus)</li> </ul>		
□ No □ Yes		
☐ Opzelura-Prior trial for 8 weeks and failure or contraindication to:		
<ul> <li>One topical corticosteroid of medium to high potency (i.e., mometasone, fluocinolone) AND</li> </ul>		
<ul> <li>One topical calcineurin inhibitors (tacrolimus or pimecrolimus), AND</li> </ul>		
Dupixent, AND		
o Eucrisa		
□ No □ Yes		
Criteria for Adbry:		
<ol> <li>Patient is using for moderate to severe atopic dermatitis for ages ≥ 18 years old</li> </ol>		
□ No □ Yes		
2. AND prior documented trial and failure of 30-day trialof the following:		
a. One topical corticosteroid of medium to high potency (i.e. mometasone, fluocinolone), OR		
b. One topical calcineurin inhibitor (tacrolimus or pimecrolimus)		
□ No □ Yes		
7 – Prescriber Sign-Off		
Additional Information –		
1. Please submit chart notes/medical records for the patient that are applicable to this request.		
2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting		
information that should be taken into consideration for the requested medication:		

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:	
Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is		

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility